Oncologic Outcomes of Total Pelvic Exenteration in Locally Advanced Rectal Cancer Without Neoadjuvant Treatment: A Retrospective Cohort Study
Keywords:
Rectal cancer, Pelvic exenteration, 5 years survival, Local recurrenceAbstract
Background: The retrospective analysis in total pelvic exenteration (TPE) in locally advanced rectal cancer to find the clinicopathologic variables in preoperative (age, gender, tumor size, site, tumor stage, lymph node involvement) and intraoperative (operative time, blood loss) that can be used to predict long-term survival in patients receiving total pelvic exenteration for advanced primary rectal cancer without neoadjuvant therapy.
Methods: 104 individual medical records with curative total pelvic exenteration for locally advanced rectal cancer had they are reviewed. On long-term survival, the effects of several clinical factors were examined.
Results: The five-year survival rate after total pelvic exenteration was 62.5 percent. The five-year survival rate was 88.9% in Stage II and 57.0% in Stage III, with zero 30 days mortality rate. Univariate analysis showed that postoperative survival was affected by tumor stage, lymphovascular invasion (LVI), intraoperative blood loss, operative time, postoperative complication, occur local recurrence, and occur distant metastasis.
Conclusion: TPE can offer long-term survival and effective local control for patients with clinical T4 or locally advanced rectal cancer.
References
Salem ME, Hartley M, Unger K, et al. Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction. Oncology (Williston Park). 2016;30(6):546-62.
Hunter CJ, Garant A, Vuong T, et al. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment. Ann Surg Oncol. 2012;19(4):1199-205.
Taylor FG, Quirke P, Heald RJ, et al. Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;1;32(1):34-43.
Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. Dis Colon Rectum. 2013;56:519–31.
Agha R, Abdall-Razak A, Crossley E, et al. for the STROCSS Group. The STROCSS 2019 Guideline: Strengthening the Reporting of Cohort Studies in Surgery. International Journal of Surgery 2019;72:156-65.
Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000;190(1):78-83.
Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007;14:1870-77.
Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol. 2007;33:452-58.
Ike H, Shimada H, Yamaguchi S, et al. Outcome of total pelvic exenteration for primary rectal cancer. Dis Colon Rectum. 2003;46:474-80.
Rodel C, Grabenbauer GG, Matzel KE, et al. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum. 2000;43:312–19.
Nishikawa T, Ishihara S, Emoto S, et al. Multivisceral resections for locally advanced colorectal cancer after preoperative treatment. Mol Clin Oncol. 2018;8(3):493-98.
Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol. 2008;26(2):303-12.
Detering R, Rutgers MLW, Bemelman WA, et al. Prognostic importance of circumferential resection margin in the era of evolving surgical and multidisciplinary treatment of rectal cancer: A systematic review and meta-analysis. Surgery. 2021;170(2):412-31.
Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis. 2006;8(9):800-7.
de Haas-Kock DF, Baeten CG, Jager JJ, et al. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg. 1996;83(6):781-85.
Park JS, Huh JW, Park YA, et al. A circumferential resection margin of 1 mm is a negative prognostic factor in rectal cancer patients with and without neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57(8):933-40.
Kelly SB, Mills SJ, Bradburn DM, et al. Northern Region Colorectal Cancer Audit Group. Effect of the circumferential resection margin on survival following rectal cancer surgery. Br J Surg. 2011;98(4):573-81.
Ishiguro S, Akasu T, Fujita S, et al. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery. 2009;145(2):189-95.
Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82.
Pleth Nielsen CK, Sørensen MM, Christensen HK, et al. Complications and survival after total pelvic exenteration. Eur J Surg Oncol. 2022;48(6):1362-67.
Bell SW, Walker KG, Rickard MJ, et al. Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg. 2003;90:1261–6.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–44.
Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 2011;253:798–810.
Horn F, Henze C, Heidrich K. Interleukin-6 signal transduction and lymphocyte function. Immunobiology. 2000;202:151–67.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998;92:4778–91.
Czaykowski PM, Gill S, Kennecke HF, et al. Adjuvant chemotherapy for stage III colon cancer: does timing matter? Dis Colon Rectum. 2011;54:1082–9.
Bayraktar UD, Chen E, Bayraktar S, et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011;117:2364–70.
Huh JW, Lee JH, Kim HR, et al. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg. 2013;206(5):758-63.
Bianchi G, Annicchiarico A, Morini A, et al. Three distinct outcomes in patients with colorectal adenocarcinoma and lymphovascular invasion: the good, the bad, and the ugly. Int J Colorectal Dis. 2021;36(12):2671-81.
Kim NK, Baik SH, Seong JS, et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg. 2006;244(6):1024-30.
Duzova M, Basaran H, Inan G, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Outcomes of survival, toxicity, sphincter preserving and prognostic factors. Transpl Immunol. 2021;69:101489.
Sauer R, Becker H, Hohenberger W, et al. German rectal cancer study group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004;351:1731-40.
Bosset JF., Collette L, Calais G, et al. JC EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006;355:1114-23.
Balbay MD, Slaton JW, Trane N, et al. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer 1999;86:2212-6.
Moriya Y, Akasu T, Fujita S, et al. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum. 2004;47(12):2047-54.
Milne T, Solomon MJ, Lee P, et al. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Dis Colon Rectum. 2014;57(10):1153-61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The Royal College of Surgeons of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles must be contributed solely to The Thai Journal of Surgery and when published become the property of the Royal College of Surgeons of Thailand. The Royal College of Surgeons of Thailand reserves copyright on all published materials and such materials may not be reproduced in any form without the written permission.
